ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study

被引：0
|
作者：
Shen, Jingnan
Guo, Wei
Wang, Jin
Xie, Xianbiao
Xie, Lu
Xu, Jie
Jing, Chen
Lin, Jianhua
Li, Xianan
Zhou, Yong
Wang, Guowen
Zhang, Xiaojing
Yao, Weitao
Dong, Yang
Ye, Zhaoming
Wang, Li
Zeng, Yanyan
Wu, Yongyong
Yang, Xiugao
Zhang, Yanfeng
机构：
[1] Sun Yat Sen Univ, Dept Musculoskeletal Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China
[2] Peking Univ, Peoples Hosp, Beijing, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[4] Sun Yat sen Univ, Dept Musculoskeletal, Affiliated Hosp 1, Oncol Ctr, Guangzhou, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China
[6] Fujian Med Univ, Dept Orthoped, Affiliated Hosp 1, Fuzhou, Peoples R China
[7] Hunan Canc Hosp, Changsha, Peoples R China
[8] Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu, Peoples R China
[9] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[10] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[11] Zhengzhou Univ, Henan Canc Hosp, Dept Orthoped, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[12] Shanghai Sixth Peoples Hosp, Shanghai, Peoples R China
[13] Zhejiang Univ, Dept Orthoped, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China
[14] CSPC Pharmaceut Grp Ltd, Shanghai, Peoples R China
[15] CSPC Pharmaceut Grp Ltd, Beijing, Peoples R China
[16] AlaMab, Phoenixville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11530
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
    Zhang, Yi
    Zhang, Qike
    Liu, Qingchi
    Dang, Huibing
    Gao, Sujun
    Wang, Wei
    Zhou, Hu
    Chen, Yuqing
    Ma, Liangming
    Wang, Jishi
    Yang, Haiping
    Lu, Binhua
    Yin, Hewen
    Wu, Liqing
    Suo, Shanshan
    Zhao, Qingwei
    Tong, Hongyan
    Jin, Jie
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (10) : 1579 - 1587
  • [42] OPEN-LABEL, SINGLE-ARM, MULTICENTER CONFIRMATORY PHASE 2 STUDY OF THE BITE® ANTIBODY BLINATUMOMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA
    Topp, M.
    Goekbuget, N.
    Stein, A. S.
    Bargou, R. C.
    Dombret, H.
    Fielding, A. K.
    Ribera, J. M.
    Foa, R.
    Zugmaier, G.
    Holland, C.
    Maniar, T.
    Huber, B.
    Nagorsen, D.
    Kantarjian, H. M.
    HAEMATOLOGICA, 2014, 99 : 258 - 258
  • [43] Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial
    Ren, Chao
    Mai, Zong-Jiong
    Jin, Ying
    He, Ming-Ming
    Wang, Zhi-Qiang
    Luo, Hui-Yan
    Zhang, Dong-Sheng
    Wu, Chen-Yi
    Wang, Feng
    Xu, Rui-Hua
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (09): : 2946 - +
  • [44] PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial
    Sun, Yu-Ting
    Guan, Wen-Long
    Zhao, Qi
    Wang, De-Shen
    Lu, Shi-Xun
    He, Cai-Yun
    Chen, Shuang-Zhen
    Wang, Feng-Hua
    Li, Yu-Hong
    Zhou, Zhi-Wei
    Xu, Rui-Hua
    Qiu, Miao-Zhen
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (10): : 5006 - +
  • [45] LUCY: A phase IIIb, single-arm, open-label multicenter study of olaparib in patients with HER2-negative metastatic breast cancer and a germline BRCA1/2 mutation
    Gelmon, Karen
    Walker, Graham P.
    Fisher, Graham V.
    CANCER RESEARCH, 2018, 78 (04)
  • [46] Safety and anti-tumor activity of Pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma: a phase I, open-label, single-arm study
    Schadendorf, D.
    Michielin, O.
    Nageli, M.
    Goldinger, S. M.
    Campigotto, F.
    Kriemler-Krahn, U.
    Schmid, H. A.
    Pedroncelli, A. M.
    Micaletto, S.
    Dummer, R.
    MELANOMA RESEARCH, 2016, 26 : E43 - E44
  • [47] Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer
    Forero-Torres, Andres
    Infante, Jeffrey R.
    Waterhouse, David
    Wong, Lucas
    Vickers, Selwyn
    Arrowsmith, Edward
    He, Aiwu Ruth
    Hart, Lowell
    Trent, David
    Wade, James
    Jin, Xiaoping
    Wang, Qiang
    Austin, TaShara
    Rosen, Michael
    Beckman, Robert
    von Roemeling, Reinhard
    Greenberg, Jonathan
    Saleh, Mansoor
    CANCER MEDICINE, 2013, 2 (06): : 925 - 932
  • [48] Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV Study
    Maluf, Fernando C.
    de Oliveira, Fabricio A. M.
    Liedke, Pedro E. R.
    Brust, Leandro
    Inocencio, Cristina G.
    Monteiro, Fernando S. M.
    Smaletz, Oren
    Cubero, Daniel, I
    CLINICAL GENITOURINARY CANCER, 2021, 19 (03) : E171 - E177
  • [49] Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant S-1 chemotherapy after gastrectomy: A multicenter, open-label, single-arm, prospective phase II study (OGSG1108)
    Imamura, Hiroshi
    Matsuyama, Jin
    Nishikawa, Kazuhiro
    Endo, Shunji
    Kawase, Tomono
    Kimura, Yutaka
    Fukui, Junichi
    Kawada, Junji
    Kurokawa, Yukinori
    Fujitani, Kazumasa
    Sakai, Daisuke
    Kawakami, Hisato
    Tsujinaka, Toshimasa
    Shimokawa, Toshio
    Matsubara, Yoshihiro
    Satoh, Taroh
    Furukawa, Hiroshi
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2021, 5 (06): : 776 - 784
  • [50] Pulmonary resectable mets of osteosarcoma with anti-angiogenic and chemotherapy (PROACH), an open-label, single-arm phase II clinical trial: The pathological study of the post-surgical specimens
    Bao, Q.
    Zhang, Z.
    Wen, J.
    Yang, X.
    Shen, Y.
    Zhang, W.
    ANNALS OF ONCOLOGY, 2024, 35
12345